Allgens Medical Technology CO., LTD. (SHA:688613)
China · Delayed Price · Currency is CNY 20.50
+0.88 (4.49%)
Sep 29, 2026, 3:00 PM CST
SHA:688613 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,688 | 2,783 | 2,445 | 2,968 | 3,123 | 7,368 | |
Market Cap Growth | -22.76% | 13.79% | -17.61% | -4.95% | -57.62% | - |
Enterprise Value | 1,717 | 1,791 | 1,453 | 1,960 | 2,159 | 6,416 |
Last Close Price | 19.62 | 20.27 | 18.00 | 22.10 | 23.15 | 54.08 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 311.90 | 201.07 | - | 54.73 | 32.80 | 61.00 |
Forward PE | - | 18.38 | 18.38 | 18.38 | 18.38 | 40.78 |
PS Ratio | 11.80 | 12.44 | 11.87 | 13.11 | 12.73 | 31.21 |
PB Ratio | 1.86 | 1.92 | 1.72 | 2.11 | 2.36 | 5.80 |
P/TBV Ratio | 1.93 | 2.01 | 1.81 | 2.18 | 2.44 | 6.04 |
P/FCF Ratio | - | 263.40 | - | 99.68 | 55.14 | 107.50 |
P/OCF Ratio | - | 70.46 | - | 57.43 | 30.60 | 56.78 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.54 | 8.01 | 7.05 | 8.65 | 8.80 | 27.18 |
EV/EBITDA Ratio | 91.37 | 90.97 | - | 63.61 | 24.51 | 53.01 |
EV/EBIT Ratio | - | - | - | 122.33 | 29.22 | 58.17 |
EV/FCF Ratio | - | 169.56 | - | 65.82 | 38.13 | 93.60 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.04 | 0.04 | 0.05 | 0.06 |
Debt / EBITDA Ratio | 1.57 | 2.26 | - | 1.57 | 0.67 | 0.65 |
Debt / FCF Ratio | - | 4.54 | - | 1.79 | 1.09 | 1.18 |
Net Debt / Equity Ratio | -0.68 | -0.71 | -0.70 | -0.74 | -0.76 | -0.77 |
Net Debt / EBITDA Ratio | -58.46 | -52.55 | 95.92 | -33.68 | -11.51 | -8.13 |
Net Debt / FCF Ratio | 29.63 | -97.95 | 30.27 | -34.85 | -17.91 | -14.36 |
Asset Turnover | 0.15 | 0.14 | 0.13 | 0.15 | 0.17 | 0.21 |
Inventory Turnover | 0.83 | 1.07 | 1.36 | 1.54 | 2.19 | 1.74 |
Quick Ratio | 40.88 | 13.72 | 21.68 | 22.84 | 23.03 | 19.88 |
Current Ratio | 44.83 | 14.93 | 22.89 | 23.64 | 23.57 | 20.32 |
Return on Equity (ROE) | 0.36% | 0.66% | -1.21% | 3.88% | 7.06% | 12.29% |
Return on Assets (ROA) | -0.20% | -0.02% | -1.12% | 0.67% | 3.20% | 6.18% |
Return on Invested Capital (ROIC) | -0.69% | -0.10% | -6.98% | 4.73% | 23.59% | 38.27% |
Return on Capital Employed (ROCE) | -0.30% | 0.00% | -1.80% | 1.10% | 5.20% | 8.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.32% | 0.50% | -0.52% | 1.83% | 3.05% | 1.64% |
FCF Yield | -1.23% | 0.38% | -1.35% | 1.00% | 1.81% | 0.93% |
Dividend Yield | 0.15% | 0.15% | - | 0.27% | 0.46% | 0.50% |
Payout Ratio | 17.23% | 16.48% | - | 31.47% | 42.14% | 1.03% |
Buyback Yield / Dilution | 0.34% | 1.63% | -6.36% | 1.37% | -12.14% | -19.66% |
Total Shareholder Return | 0.49% | 1.78% | -6.36% | 1.64% | -11.68% | -19.16% |